Home › Compare › RAHGF vs JNJ

RAHGF vs JNJ: Dividend Comparison 2026

RAHGF yields 2000000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RAHGF wins by $1.6247481716182984e+23M in total portfolio value
10 years
RAHGF
RAHGF
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6247481716182984e+23M
Annual income
$147,608,011,402,949,780,000,000,000,000.00
Full RAHGF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — RAHGF vs JNJ

📍 RAHGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRAHGFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RAHGF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
RAHGF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RAHGF
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$125,466,809,692,507,310,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, RAHGF beats the other by $125,466,809,692,507,310,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RAHGF + JNJ for your $10,000?

RAHGF: 50%JNJ: 50%
100% JNJ50/50100% RAHGF
Portfolio after 10yr
$8.123740858091492e+22M
Annual income
$73,804,005,701,474,890,000,000,000,000.00/yr
Blended yield
90.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

RAHGF
No analyst data
Altman Z
0.0
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RAHGF buys
0
JNJ buys
0
No recent congressional trades found for RAHGF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRAHGFJNJ
Forward yield2000000.00% ✓2.13%
Annual dividend / share$2.00$5.20 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28% ✓
Portfolio after 10y$1.6247481716182984e+23M$30.3K ✓
Annual income after 10y$147,608,011,402,949,780,000,000,000,000.00 ✓$4,689.40
Total dividends collected$1.6146053563276882e+23M$15.4K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RAHGF vs JNJ ($10,000, DRIP)

YearRAHGF PortfolioRAHGF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$100,010,700$100,000,000.00$10,592$272.30+$100.00M → RAHGF
2$467,446,731,075$467,339,719,626.17$11,289$357.73+$467446.72M → RAHGF
3$1,021,215,363,816,662$1,020,715,195,814,411.90$12,123$472.89+$1021215363.80M → RAHGF
4$1,043,112,617,104,109,200$1,042,019,916,664,825,300.00$13,141$629.86+$1043112617104.10M → RAHGF
5$498,482,143,759,731,400,000$497,366,013,259,430,040,000.00$14,408$846.81+$498482143759731.38M → RAHGF
6$111,599,275,650,097,780,000,000$111,065,899,756,274,860,000,000.00$16,021$1,151.60+$111599275650097776.00M → RAHGF
7$11,738,678,336,351,557,000,000,000$11,619,267,111,405,953,000,000,000.00$18,122$1,588.22+$11738678336351557632.00M → RAHGF
8$583,674,362,697,175,100,000,000,000$571,113,976,877,278,900,000,000,000.00$20,930$2,228.20+$583674362697175072768.00M → RAHGF
9$13,894,210,989,607,547,000,000,000,000$13,269,679,421,521,570,000,000,000,000.00$24,792$3,191.91+$1.3894210989607547e+22M → RAHGF
10$162,474,817,161,829,840,000,000,000,000$147,608,011,402,949,780,000,000,000,000.00$30,274$4,689.40+$1.6247481716182984e+23M → RAHGF

RAHGF vs JNJ: Complete Analysis 2026

RAHGF — Stock

Roan Holdings Group Co., Ltd., through its subsidiaries, provides financial, insurance, and healthcare related solutions to individuals, and micro, small, and medium-sized enterprises in China. It offers health management, health big data management, and blockchain technology-based health information management, as well as asset management, factoring, and consumer financing services to the employees of large institutions. Further, it provides supply chain management, financial advisory, consulting services related to debt collection, and management and assessment services, as well as loans to third parties, SME and consumer financing, equity, currency integrated payment application, travel consumption, multimedia real-time multi-threaded interactive technology application, oncology treatment and products, and one-stop internet service platform. The company was formerly known as China Lending Corporation and changed its name to Roan Holdings Group Co., Ltd. in January 2020. Roan Holdings Group Co., Ltd. was founded in 2009 and is based in Hangzhou, the People's Republic of China.

Full RAHGF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this RAHGF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RAHGF vs SCHDRAHGF vs JEPIRAHGF vs ORAHGF vs KORAHGF vs MAINRAHGF vs ABBVRAHGF vs MRKRAHGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.